CATALYST PHARMACEUTICALS INC (CPRX) Fundamental Analysis & Valuation

NASDAQ:CPRX • US14888U1016

Current stock price

23.37 USD
+0.58 (+2.54%)
Last:

This CPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CPRX Profitability Analysis

1.1 Basic Checks

  • CPRX had positive earnings in the past year.
  • In the past year CPRX had a positive cash flow from operations.
  • In the past 5 years CPRX has always been profitable.
  • In the past 5 years CPRX always reported a positive cash flow from operatings.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 19.41%, CPRX belongs to the top of the industry, outperforming 96.34% of the companies in the same industry.
  • CPRX has a better Return On Equity (22.46%) than 95.95% of its industry peers.
  • CPRX's Return On Invested Capital of 20.39% is amongst the best of the industry. CPRX outperforms 97.69% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CPRX is in line with the industry average of 18.89%.
  • The last Return On Invested Capital (20.39%) for CPRX is above the 3 year average (19.09%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 19.41%
ROE 22.46%
ROIC 20.39%
ROA(3y)17.95%
ROA(5y)18.52%
ROE(3y)21.13%
ROE(5y)22.03%
ROIC(3y)19.09%
ROIC(5y)20.07%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • CPRX has a better Profit Margin (36.39%) than 96.53% of its industry peers.
  • CPRX's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 43.77%, CPRX belongs to the best of the industry, outperforming 99.04% of the companies in the same industry.
  • CPRX's Operating Margin has improved in the last couple of years.
  • CPRX has a Gross Margin of 85.19%. This is amongst the best in the industry. CPRX outperforms 87.67% of its industry peers.
  • In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
Industry RankSector Rank
OM 43.77%
PM (TTM) 36.39%
GM 85.19%
OM growth 3Y-2.71%
OM growth 5Y4.77%
PM growth 3Y-2.11%
PM growth 5Y-10.39%
GM growth 3Y0.49%
GM growth 5Y-0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CPRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
  • Compared to 1 year ago, CPRX has more shares outstanding
  • The number of shares outstanding for CPRX has been increased compared to 5 years ago.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 13.87 indicates that CPRX is not in any danger for bankruptcy at the moment.
  • CPRX's Altman-Z score of 13.87 is amongst the best of the industry. CPRX outperforms 85.93% of its industry peers.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 13.87
ROIC/WACC2.2
WACC9.28%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 6.08 indicates that CPRX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.08, CPRX is doing good in the industry, outperforming 63.20% of the companies in the same industry.
  • A Quick Ratio of 5.82 indicates that CPRX has no problem at all paying its short term obligations.
  • The Quick ratio of CPRX (5.82) is better than 62.62% of its industry peers.
Industry RankSector Rank
Current Ratio 6.08
Quick Ratio 5.82
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. CPRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.01% over the past year.
  • CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.75% yearly.
  • Looking at the last year, CPRX shows a quite strong growth in Revenue. The Revenue has grown by 19.78% in the last year.
  • CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.67% yearly.
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
Revenue 1Y (TTM)19.78%
Revenue growth 3Y40.1%
Revenue growth 5Y37.67%
Sales Q2Q%7.61%

3.2 Future

  • Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.46% on average per year.
  • CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.11% yearly.
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue Next Year9.02%
Revenue Next 2Y9.76%
Revenue Next 3Y9.32%
Revenue Next 5Y9.11%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. CPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 13.83 indicates a correct valuation of CPRX.
  • Based on the Price/Earnings ratio, CPRX is valued cheaply inside the industry as 95.57% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 25.23. CPRX is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 12.10 indicates a correct valuation of CPRX.
  • Based on the Price/Forward Earnings ratio, CPRX is valued cheaply inside the industry as 97.11% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.42. CPRX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 13.83
Fwd PE 12.1
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaper than 97.69% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CPRX is valued cheaply inside the industry as 96.72% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.68
EV/EBITDA 7.01
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of CPRX may justify a higher PE ratio.
PEG (NY)0.97
PEG (5Y)0.42
EPS Next 2Y13.06%
EPS Next 3Y6.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPRX Dividend Analysis

5.1 Amount

  • CPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPRX Fundamentals: All Metrics, Ratios and Statistics

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (3/23/2026, 1:05:05 PM)

23.37

+0.58 (+2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners88.61%
Inst Owner Change-0.37%
Ins Owners5.59%
Ins Owner Change0.25%
Market Cap2.85B
Revenue(TTM)588.99M
Net Income(TTM)214.33M
Analysts88.57
Price Target35.19 (50.58%)
Short Float %8.13%
Short Ratio7.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.83%
Min EPS beat(2)19.63%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)19.39%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)17.18%
EPS beat(12)10
Avg EPS beat(12)14.79%
EPS beat(16)13
Avg EPS beat(16)11.51%
Revenue beat(2)2
Avg Revenue beat(2)5.84%
Min Revenue beat(2)5.34%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.83%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.89%
Revenue beat(12)11
Avg Revenue beat(12)3.56%
Revenue beat(16)14
Avg Revenue beat(16)3.41%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.27%
EPS NQ rev (3m)21.62%
EPS NY rev (1m)6.4%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)3.06%
Revenue NQ rev (3m)3.39%
Revenue NY rev (1m)1.93%
Revenue NY rev (3m)1.79%
Valuation
Industry RankSector Rank
PE 13.83
Fwd PE 12.1
P/S 4.85
P/FCF 13.68
P/OCF 13.68
P/B 2.99
P/tB 3.47
EV/EBITDA 7.01
EPS(TTM)1.69
EY7.23%
EPS(NY)1.93
Fwd EY8.27%
FCF(TTM)1.71
FCFY7.31%
OCF(TTM)1.71
OCFY7.31%
SpS4.82
BVpS7.81
TBVpS6.74
PEG (NY)0.97
PEG (5Y)0.42
Graham Number17.24
Profitability
Industry RankSector Rank
ROA 19.41%
ROE 22.46%
ROCE 26.94%
ROIC 20.39%
ROICexc 78.78%
ROICexgc 168.22%
OM 43.77%
PM (TTM) 36.39%
GM 85.19%
FCFM 35.42%
ROA(3y)17.95%
ROA(5y)18.52%
ROE(3y)21.13%
ROE(5y)22.03%
ROIC(3y)19.09%
ROIC(5y)20.07%
ROICexc(3y)57.9%
ROICexc(5y)154.04%
ROICexgc(3y)178.31%
ROICexgc(5y)N/A
ROCE(3y)25.22%
ROCE(5y)26.51%
ROICexgc growth 3YN/A
ROICexgc growth 5Y9.61%
ROICexc growth 3Y-41.48%
ROICexc growth 5Y-5.82%
OM growth 3Y-2.71%
OM growth 5Y4.77%
PM growth 3Y-2.11%
PM growth 5Y-10.39%
GM growth 3Y0.49%
GM growth 5Y-0.11%
F-Score6
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.15%
Cap/Sales 0.01%
Interest Coverage 553.17
Cash Conversion 70.58%
Profit Quality 97.33%
Current Ratio 6.08
Quick Ratio 5.82
Altman-Z 13.87
F-Score6
WACC9.28%
ROIC/WACC2.2
Cap/Depr(3y)0.78%
Cap/Depr(5y)100.47%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)148.03%
Profit Quality(5y)146.81%
High Growth Momentum
Growth
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue 1Y (TTM)19.78%
Revenue growth 3Y40.1%
Revenue growth 5Y37.67%
Sales Q2Q%7.61%
Revenue Next Year9.02%
Revenue Next 2Y9.76%
Revenue Next 3Y9.32%
Revenue Next 5Y9.11%
EBIT growth 1Y32.11%
EBIT growth 3Y36.3%
EBIT growth 5Y44.23%
EBIT Next Year28.53%
EBIT Next 3Y17.44%
EBIT Next 5YN/A
FCF growth 1Y-12.81%
FCF growth 3Y21.61%
FCF growth 5Y35.9%
OCF growth 1Y-12.98%
OCF growth 3Y21.62%
OCF growth 5Y35.91%

CATALYST PHARMACEUTICALS INC / CPRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPRX.


What is the valuation status for CPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.


Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?

CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 8 / 10.


What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?

The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 14.31% in the next year.